摘要
背景与目的:目前多基因、多靶点联合治疗已成为肿瘤研究的方向之一,本文探讨重组人血管内皮抑素(endostatin,ES)联合重组人p53腺病毒(rAd/p53)对乳腺癌裸鼠移植瘤的抑制作用。方法:建立人乳腺癌裸鼠模型,成瘤后随机分为对照组、ES组、rAd/p53组和联合组,分别给予处理;观察裸鼠的一般情况、体重和肿瘤的体积,并检测肿瘤组织微血管密度(MVD,microvessel density)和血管内皮生长因子(VEGF,vascular endothelial growth fac-tor)的表达。结果:成瘤后ES组,rAd/p53组和联合组抑瘤率分别为1.75%、43.36%和58.68%,rAd/p53组和联合组可明显抑制肿瘤生长(P<0.05),联合组抑瘤作用更为显著;对照组、ES组、rAd/p53组与联合组肿瘤组织的MVD及VEGF表达H-评分分别为(30±5、24±4、24±4、18±4)和(46±8、39±8、40±5、29±5),联合组均低于其余各组,差异有显著性(P<0.05);各组均未见不良反应,体重变化无显著性(P>0.05)。结论:重组人血管内皮抑素联合rAd/p53可显著抑制裸鼠乳腺癌的生长及微血管生成。
Background and purpose：There is a tendency to treat tumors through multiple genes and multiple targeting but there has been no reports about the therapeutic effect of recombinant human endostatin（ES）combined with rAd/p53 on graft model of human breast cancer.Methods：MCF-7 human breast cancer cells were inoculated in nude mice.Then the nude mice with xenograft tumor were randomized into groups of control,ES,rAd/p53,and ES ＋ rAd/p53,they were treated according to the plan.Diversity of the xenograft tumor volume and side effect was observed.Microvessel density（MVD）and expression of vascular endothelial growth factor（VEGF）were detected by immunohistochemistry.Results：After the administration of ES,rAd/p53,ES ＋ rAd/p53,the growth of tumor was inhibited with the inhibitory rate of 1.75%,43.36% and 58.68%,respectively.Inhibition of tumor growth was significant in Group rAd/p53 and ES ＋ rAd/p53（P〈0.05）,MVD and H-score of VEGF in group control,ES,rAd/p53,ES ＋ rAd/p53 were 30±5,24±4,24±4,18±4 and 46±8,39±8,40±5,29±5,of which group ES ＋ rAd/p53 were obviously lower than other groups（P〈0.05）.There was no side effect to be documented,and the body weight of nude mice had not been changed markedly in all groups（P〉0.05）.Conclusions：recombinant human endostatin combined with rAd/p53 can greatly inhibit growth of xenograft tumor,and reduce the generation of capillary vessels.
出处
《中国癌症杂志》
CAS
CSCD
2007年第11期843-846,共4页
China Oncology
